Veracyte, Inc. (FRA:12V)

Market Cap	3.23B
Revenue (ttm)	422.01M
Net Income (ttm)	25.84M
Shares Out	n/a
EPS (ttm)	0.32
PE Ratio	124.90
Forward PE	28.53
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	22
Open	41.00
Previous Close	40.80
Day's Range	41.00 - 41.00
52-Week Range	19.50 - 44.60
Beta	n/a
RSI	67.69
Earnings Date	Feb 25, 2026

About Veracyte

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2006
• Employees: 824
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 12V

Financial Performance

Financial numbers in USD